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The ESR1 gene polymorphisms in patients with coronary artery
disease in the southeastern Turkish population
Abdussemet HAZAR1, Fuat DİLMEÇ2, Aydemir KOÇARSLAN1, Mustafa GÖZ1,
Mehmet Salih AYDIN1, Abbas Heval DEMİRKOL1

Aim: The objective of this study was to evaluate the prevalence of the estrogen receptor 1 (ESR1) gene variants and their
possible association with coronary artery disease (CAD) in Şanlıurfa province.
Materials and methods: We used polymerase chain reaction and restriction enzyme digestion to determine the
prevalence of the ESR1 gene (NM_001122742.1, GI: 2099): c.454-351 A>G (XbaI A>G) and c.454-397 T>C (PvuII T>C)
polymorphisms in 100 healthy individuals and 80 angiographically confirmed CAD patients.
Results: The body mass index (28.1 ± 5.4), low-density lipoprotein cholesterol (126.1 ± 42 mg/dL), diabetes (n = 13),
and hypertension (n = 39) values of the CAD patients were significantly higher than in the control subjects (26.2 ± 3.9,
106.1 ± 26.3, 2, and 18, respectively) (P < 0.05). No significant differences were observed in the frequencies of both the
c.454-351 A>G and c.454-397 T>C genotype of the ESR1 gene in CAD patients compared to healthy individuals (P >
0.05).
Conclusion: The ESR1 variants tested in this study were not associated with CAD. Therefore, neither of these 2 variants
can be considered as an independent risk factor or a predictor for CAD in the studied Turkish population.
Key words: Coronary artery disease, estrogen receptor 1 gene, polymorphism, polymerase chain reaction, restriction
fragment length polymorphism, single nucleotide polymorphism

Introduction
Coronary artery disease (CAD) is a multifactorial
disorder. Sex plays an important role in the
pathogenesis of CAD by mechanisms that are still
mostly unknown to us (1).The sex hormone estrogen
has been found as the first potential cardioprotection
factor in women, and the binding of estrogen to its
receptor triggers estrogenic effects on various tissues
(2,3). The estrogen receptor 1 (ESR1) gene is located
on human chromosome 6 (6p25.1) and consists
of 8 exons and 7 introns, spanning 412,779 bp (4).
The ESR1 gene encodes an estrogen receptor α, a
ligand-activated transcription factor composed of
several domains important for hormone binding,

DNA binding, and activation of transcription (5).
The effects of estrogens on the vascular system are
mediated mainly through ESR1, a member of the
nuclear hormone receptor super family, acting as a
ligand-activated transcription factor (6-8).
A number of studies have indicated that the
c.454-351 A>G (XbaI, rs9340799) and c.454-397
T>C (PvuII, rs2234693) polymorphic variations in
the first intron of the ESR1 gene are associated with
different factors, such as the onset of menopause,
bone density, arterial hypertension, and body mass
index (BMI) (9-13).
ESR1 is an interesting candidate gene because
estrogen has beneficial effects on cardiovascular
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health. Of the polymorphisms identified in the ESR1
gene, 2 single nucleotide polymorphisms (SNPs),
c.454-351 A>G and c.454-397 T>C, are most widely
investigated (14,15).
Various studies pointed out that the frequencies of
the c.454-351 A>G and c.454-397 T>C genotype and
allele were not significantly different between CAD
patients and controls in various populations (2,8,1419). On the other hand, some studies indicated that
homozygosity for the alleles of the c.454-351 G
and c.454-397 C polymorphisms were significantly
associated with increased severity of CAD in males
or females in different populations (20-23). These
findings suggest that ESR1 is a novel candidate gene
for CAD.
In this study, we aimed to investigate the
association of CAD with the frequencies of ESR1
polymorphisms, and to see whether they are
important genetic risk factors for CAD in a Turkish
population.
Materials and methods
Study population and DNA extraction
This study was conducted from September 2008 to
August 2009 in Turkey. Enrolled into the study were 80
consecutive patients who applied to the Department
of Cardiovascular Surgery and Cardiology at Harran
University Medical Faculty Hospital with CAD (38
females, mean age 53.07 ± 11.1 years, and 42 males,
mean age 56.7 ± 5.9 years) and who had 1 or more
coronary lesions causing ≥50% stenosis. The presence
and severity of CAD was determined by the Gensini
score (24). Exclusion criteria were the presence of
any of the following: stable angina pectoris with
normal coronary arteries or with <50% stenosis in
major coronary arteries; acute coronary syndrome;
cerebrovascular disease; known renal, hepatic,
or immunologic disorders; obesity secondary
to hypothyroidism or Cushing’s disease; severe
debilitating diseases; and malignancy. From among
blood donors, 100 healthy controls (51 females, mean
age 54.9 ± 8.6 years, and 49 males, mean age 57.5 ±
9.6 years) who did not have any disease and had no
clinical evidence of a family history in first-degree
relatives of CAD or other disorders were randomly
selected.

Demographic details, including anthropometric
measurements, cardiovascular risk factors, and
medication use, were recorded for all participants.
BMI was calculated as weight in kilograms divided by
the square of the height in meters (kg/m2). The levels
of triglycerides (TG), total cholesterol, high-density
lipoprotein cholesterol (HDL-c), and low-density
lipoprotein cholesterol (LDL-c) were determined
by using commercially available assay kits (Abbott®,
Abbott Park, Illinois, USA) with an Abbott Aeroset
automatic analyzer (Abbott®).
EDTA blood was taken from these individuals,
and genomic DNA was extracted from whole
blood leukocytes by using the standard salting-out
procedure (25).
PCR-RFLP technique
The c.454-351 A>G (g.34720 A>G, rs9340799)
and c.454-397 T>C (g.34650 T>C, rs2234693)
polymorphic sites of the ESR1 (NM_001122742.1; GI:
2099) gene were investigated by the polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) technique. The PCR reactions were
performed in 20 μL of reaction volume, including
1X PCR buffer, 2 mM MgCl2, 0.2 mM each of
deoxynucleotide triphosphates (dNTPs; Fermentas,
St. Leon-Rot, Germany), 0.2 μM of each primer
(A: GCCACCCTATCTGTATCTTTTCCTATTCTTC
-3, B: TCTCTGCCACCCTGGCGTCGATTATCTGA
-3’) (26) (Bio Basic Inc., Ontario, Canada), 40 ng of DNA,
and 0.5 units of Taq DNA polymerase (Fermentas).
The PCR program for the 2 polymorphic sites was
performed at 94 °C for 3 min (initial denaturation),
then 30 cycles of 94 °C for 50 s, 62 °C for 50 s, 72
°C for 50 s, and a final extension of 72 °C for 5 min.
Ten microliters of PCR product in a 30-μL
volume for c.454-351 A>G and c.454-397 T>C
was separately digested with 1.5 units of XbaI
and PvuII restriction enzymes (Fermentas,
St. Leon-Rot, Germany) at 37 °C for 2 h.
The digested PCR products were separated on
1.5% agarose gel and analyzed using the AlphaImager
Imaging System (AlphaInnotech, San Leandro,
California, USA). The digested ESR1: c.454-351 A
allele yielded 2 fragments of 981 and 393 bp, and the
G allele yielded 1 fragment of 1374 bp (Figure 1). The
c.454-397 T allele yielded 2 fragments of 936 and 438
bp, and the C allele yielded 1 fragment of 1374 bp
(Figure 2).
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Figure 1. The restriction profile of the ESR1 gene XbaI (c.454351 A>G). Lane M: DNA marker (100-1500 bp, Bio
Basic Inc., Ontario, Canada), lane 1: undigested
PCR product, lane 2: GG genotype (homozygous,
polymorphic), lane 3: AG genotype (heterozygous),
lane 4: AA genotype (homozygous, wild type).

Figure 2. The restriction profile of the ESR1 gene PvuII (c.454397 T>C). Lane M: DNA marker (100-1500 bp, Bio
Basic Inc.), lane 1: undigested PCR product, lane 2:
CC genotype (homozygous, polymorphic), lane 3:
TC genotype (heterozygous), lane 4: TT genotype
(homozygous, wild type).

Statistical analysis
Student’s t-test was used for continuous variables
that showed normal distribution according to the
one-sample K-S test, and the Mann-Whitney U test
was used for variables that did not show normal
distribution. Categorical variables were compared
by using the chi-square test. Genotype and allele
frequencies of ESR1: c.454-351 A>G and c.454-397
T>C were tested for Hardy-Weinberg equilibrium
by using the chi-square test. Genotype and allele
frequencies of these polymorphisms were analyzed
with Fisher’s exact test. Statistical significance was
defined as P < 0.05.

Ethics
All patients gave written informed consent before
being recruited. The study was approved by the
institutional ethics committee.
Results
The baseline characteristics of the patients and
controls are presented in Table 1. The frequency of
sex and age of patients with CAD and of the healthy
controls did not differ between the study groups (P

Table 1. The demographic parameters of the patients with CAD and the control group.

Sex (F/M)
Age (years)
BMI (kg/m2)
TG (mg/dL)
HDL-c (mg/dL)
LDL-c (mg/dL)
Diabetes (n)
Smoking (n)
Hypertension (n)
Gensini score (mean ± SD)

CAD patients
(n = 80)

Controls
(n = 100)

38/42
54.9 ± 8.8
28.1 ± 5.4
164.7 ± 89.0
40.6 ± 24.5
126.1 ± 42.5
13
15
39
48.46 ± 31.46

51/49
56.2 ± 9.2
26.2 ± 3.9
167.2 ± 47.4
38.1 ± 9.5
106.1 ± 26.3
2
17
18

Values are mean ± standard deviation (SD).
Chi-square, bStudent’s t-test, cMann-Whitney U test.

a
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P-value
a

0.641
0.342
b
0.006
b
0.810
c
0.985
b
0.001
a
0.001
a
0.760
a
0.001
b
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Table 2. ESR1 gene polymorphisms in a Turkish population with CAD and the control group.
SNP
genotype/allele
c.454-351A>G
Genotypes
AA
AG
GG
Alleles
A
G
c.454-397T>C
Genotypes
TT
TC
CC
Alleles
T
C

CAD patients
(n = 80)

Healthy controls
(n = 100)

35 (43.8%)
31 (38.8%)
14 (17.5%)

X2

OR (95% CI)

*P-value

43 (43.0%)
46 (46.0%)
11 (11.0%)

0.954
1.570

Reference
0.743 (0.409-1.350)
1.716 (0.732-4.021)

0.329
0.210

101 (63.1%)
59 (36.9%)

132 (66.0%)
68 (34.0%)

0.322

Reference
1.134 (0.734-1.751)

0.571

31 (38.8%)
37 (46.2%)
12 (15.0%)

39 (39.0%)
47 (47.0%)
14 (14.0%)

0.010
0.036

Reference
0.970 (0.538-1.749)
1.084 (0.471-2.496)

0.920
0.850

99 (61.9%)
61 (38.1%)

125 (62.5%)
75 (37.5%)

0.015

Reference
1.027 (0.669-1.577)

0.903

CAD - coronary artery disease, X2 - chi-squared, OR - odds ratio, CI - confidence interval, SNP - single nucleotide polymorphism.
*Chi-square and Fisher’s exact tests.

= 0.641 and P = 0.342, respectively). The BMI and
LDL-c values and the prevalence of diabetes and
hypertension were significantly higher in the CAD
group than in the healthy subjects (P = 0.006, P =
0.001, P = 0.001, and P = 0.001, respectively), while
there were no statistically significant differences
in TG and HDL-c or in the prevalence of current

cigarette smoking (P = 0.810, P = 0.985, and P =
0.760, respectively).
The distribution of the genotypes for the c.454351 A>G and c.454-397 T>C polymorphic sites was
consistent with the Hardy-Weinberg equilibrium
in the CAD and control groups (P > 0.05). For the

Table 3. The demographic and clinical profiles with and without polymorphic genotype for the ESR1 gene in patients with CAD.

c.454-351A>G
Genotype
Subjects (n)
Sex (F/M)
Age (years)
BMI (kg/m2)
TG (mg/dL)
HDL-c (mg/dL)
LDL-c (mg/dL)
Diabetes
Smoking
Hypertension

AA
35
13/22
54.1 ± 7.9
27.7 ± 4.7
183.5 ± 115.1
36.5 ± 7.1
129.3 ± 44.6
6
6
16

GG
14
5/9
56.6 ± 9.4
29.2 ± 6.6
130.2 ± 64.5
50.6 ± 53.1
118.9 ± 38.2
2
2
11

c.454-397T>C
P-value
0.925
0.350
0.360
0.111
0.126
0.450
0.807
0.807
0.037

TT
31
12/19
53.8 ± 8.4
27.9 ± 4.8
177.2 ± 106.4
36.6 ± 7.4
123.2 ± 44.0
6
6
16

CC
12
6/6
56.1 ± 9.8
29.3 ± 5.2
152.0 ± 112.1
52.8 ± 57.1
126.9 ± 42.5
2
3
8

P-value
0.501
0.456
0.406
0.496
0.122
0.805
0.839
0.683
0.373

Values are mean ± SD, AA (XbaI) - wild-type genotype, TT (PvuII) - wild-type genotype, GG (XbaI) - polymorphic genotype, CC
(PvuII) - polymorphic genotype.
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Table 4. The relation of ESR1 gene polymorphism genotypes and allele frequencies with CAD and control groups by sex.
SNP
CAD patients Healthy controls
c.454-351A>G
(n = 80)
(n = 100)
Women
Genotypes
AA
AG
GG
Alleles
A
G
Men
Genotypes
AA
AG
GG
Alleles
A
G

*P-value

38

51

13 (34.2%)
20 (52.6%)
5 (13.2%)

22 (43.1%)
25 (49.0%)
4 (7.8%)

Reference
0.736
0.411

46 (60.5%)
30 (39.5%)

69 (68.3%)
33 (31.7%)

Reference
0.282

42

49

22 (52.4%)
11 (26.2%)
9 (21.4%)

21 (42.9%)
21 (42.9%)
7 (14.3%)

Reference
0.097
0.372

55 (65.5%)
29 (34.5%)

63 (64.3%)
35 (35.7%)

Reference
0.867

SNP
CAD patients Healthy controls
c.454-397T>C
(n = 80)
(n = 100)
Women
Genotypes
TT
TC
CC
Alleles
T
C
Men
Genotypes
TT
TC
CC
Alleles
T
C

*P-value

38

51

12 (31.6%)
20 (52.6%)
6 (15.8%)

14 (27.5%)
26 (51.0%)
11 (21.6%)

Reference
0.877
0.493

44 (57.9%)
32 (42.1%)

54 (52.9%)
48 (47.1%)

Reference
0.511

42

49

19 (45.2%)
17 (40.5%)
6 (14.3%)

25 (51.0%)
21 (42.9%)
3 (6.1%)

Reference
0.818
0.193

55 (65.5%)
29 (34.5%)

71 (72.4%)
27 (27.6%)

Reference
0.310

CAD - coronary artery disease, SNP - single nucleotide polymorphism.
*Chi-square and Fisher’s exact tests.

c.454-351 polymorphism, the GG genotype and
G allele frequencies in CAD individuals were not
significantly higher than those in healthy individuals
(17.5% and 36.9% vs. 11.0% and 34.0%, P = 0.210 vs.
P = 0.571, respectively) (Table 2). Furthermore, there
was no significant difference between CAD patients
and healthy controls for the c.454-397 CC genotype
(15.0% vs. 14.0%, P = 0.850) or C allele (38.1% vs.
37.5%, P = 0.903) frequencies (Table 2).
No significant difference was found between
CAD patients with and without c.454-351 A>G
polymorphism (GG genotype and AA genotype wildtype) in terms of sex, age, BMI, TG, HDL-c, LDL-c,
diabetes, and current cigarette smoking (P > 0.05 for
all), but hypertension was more frequent in the AA
genotype (P = 0.037). On the other hand, there was
no statistically significant difference between patients
with and without the c.454-397 T>G polymorphism
(CC genotype and TT genotype wild-type) in terms
of all the mentioned risk factors (P > 0.05 for all)
(Table 3).
Subgroup analysis by sex did not demonstrate any
significant relationship (P > 0.05 for men and P >
0.05 for women). In addition, the subgroup analysis
1054

by sex revealed that the relationship between the
ESR1 c.454-397 polymorphism and CAD patients
was not significant (P > 0.05 for men and P > 0.05 for
women) (Table 4).
Discussion
Coronary heart disease is the leading cause of
mortality worldwide (27, 28). Estrogens are known to
regulate the cardiovascular system via both systemic
effects on circulating factors (e.g. cholesterol,
lipoproteins, triglycerides) and via direct effects on
the blood vessel wall (e.g. vascular, cell proliferation).
However, the genetic factors underlying this form of
cardiovascular disease are complex and not clearly
established (29).
In investigating the impacts of 2 intronic
polymorphisms of the ESR1 gene on the risk of
CAD in a Turkish population, we did not find an
association of ESR1 c.454-351 A>G and c.454-397
T>C genotypes and alleles with CAD. Although the
frequencies of the c.454-351 GG genotype (17.5%)
and G allele (36.9%) in CAD patients were higher
than those in healthy subjects (11.0% and 34.0%,
respectively), these differences were not significant

A. HAZAR, F. DİLMEÇ, A. KOÇARSLAN, M. GÖZ, M. S. AYDIN, A. H. DEMİRKOL

(P > 0.05 for both). Similarly, we did not observe
an association between CAD and the frequencies of
the ESR1: c.454-397 CC genotype and C allele (P >
0.05). On the other hand, no sex-specific differences
were detected, either. Thus, our findings for sex are
in agreement with the findings of a recent study
conducted by Karadag et al (2). Although several
studies had been performed on this topic, inconsistent
results were obtained from different populations.
Xu et al in a Chinese population (16), Boroumand
et al in an Iranian population (14, 15), Matsubara
et al in a Japanese population (18), and LluísGanella et al in a Spanish population (19) showed
that genotype distributions and allele frequencies of
c.454-351 A>G or c.454-397 T>C polymorphisms
are not significantly different between control
subjects and patients (14-16, 18, 19). When the allele
frequencies are analyzed separately according to sex,
age, cigarette smoking, and hyperlipidemia, there
is still no statistically significant difference for both
polymorphisms. In the Central Anatolia Region of
Turkey, Yilmaz et al indicated that the ESR1:c.454-397
T>C polymorphism, but not the c.454-351 A>G
polymorphism, was associated with CAD, and the C
allele for the c.454-397 T>C polymorphism was found
to be an independent determinant of the presence of
CAD (26). In another study in a Turkish population
(in the Marmara region of Turkey), Karadağ et al.
reported that no association was found between the
CAD and c.454-397 T>C polymorphism genotypes
and alleles and, in addition, subgroup analysis by
sex did not demonstrate any significant relation,
either (2). This is, to our knowledge, the third study
investigating whether ESR1 polymorphisms are
associated with CAD patients in Turkey. Our study
is important, though, because it is the first such work
in Şanlıurfa Province (southeastern Anatolia region
of Turkey). Although there has been controversy
about the relationship between ESR1 polymorphisms
and CAD, our findings are similar to those of several
previous reports (2,14-16,18,19). It is also worth
mentioning that our study is the first study performed
in patients with CAD in our population. On the other
hand, c.454-351 A>G and c.454-397 T>C genotype
distributions were significantly different between the
CAD and non-CAD groups in an Israeli population,
a Greek population, and in postmenopausal women
and in men in a Japanese population (22,23).
Diabetes, hypertension, high LDL-c levels, and
the ESR1: c.454-397 CC genotype were independent

risk factors for CAD, and the c.454-397 CC genotype
was associated with the angiographic severity of CAD
measured by the number of diseased vessels as well
as c.454-351A>G, but no association was found with
CAD susceptibility before or after sex stratification.
In addition, no association was found between the
polymorphisms and the angiographic severity of
CAD (16).
Total cholesterol, TG, and HDL-c levels were
previously found not to be different among ESR
genotypes (18). Our results were consistent with data
reported previously (16,18). In our study, comparison
of CAD patients without the c.454-351 AA wild-type
genotype and those with the polymorphic c.454-351
GG genotype showed no association in terms of age,
BMI, TG, HDL-c, LDL-c, diabetes, and smoking
(P > 0.05), but did show an association in terms of
hypertension (P < 0.05). However, we did not find
a statistically significant difference between patients
without the wild-type TT genotype and those with
the polymorphic CC genotype in terms of clinical
and demographic variants for the c.454-397 A>G
polymorphism (P > 0.05).
The limited number of patients and healthy
individuals is the most important limitation of the
study. Furthermore, our data indicated that there were
no statistically significant differences in TG, HDL-C,
and the prevalence of current cigarette smoking
between the CAD group and healthy subjects, while
the levels of BMI and LDL-C and the frequencies of
diabetes and hypertension were significantly higher
in the CAD group. This unexpected result is also
related to the limited number of subjects.
In conclusion, we found that the ESR1 gene
c.454-351 A>G and c.454-397 T>C polymorphisms
are not important risk factors for CAD in a Turkish
population in the southeastern Anatolia region
of Turkey. However, studies of larger numbers of
patients and controls in various populations will be
required in order to determine the influence of these
genes and other candidate genes and SNPs on the risk
of CAD.
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